Table 3 Absolute and percent change from baseline in excess CST to Weeks 2, 4, and 8 (FAS)
ASP8232 | ASP8232/ranibizumab | Ranibizumab | |
|---|---|---|---|
Baseline | |||
n | 32 | 32 | 31 |
Mean (SD) | 215.8 (117.9) | 191.8 (103.9) | 181.6 (105.5) |
Week 2 | |||
n | 31 | 32 | 30 |
Mean (SD) | 230.9 (134.3) | 62.3 (109.1) | 71.5 (85.3) |
%CFB | 16.3 (39.4) | − 69.3 (55.4) | − 57.6 (51.9) |
Week 4 | |||
n | 32 | 32 | 31 |
Mean (SD) | 223.1 (130.6) | 76.7 (115.0) | 88.8 (109.0) |
%CFB | 11.6 (44.1) | − 56 (57.0) | − 50.2 (64.4) |
Week 8 | |||
n | 32 | 32 | 29 |
Mean (SD) | 224.5 (110.1) | 64.9 (114.8) | 69.4 (118.8) |
%CFB | 17.7 (57.1) | − 55.1 (77.3) | − 66.0 (57.0) |